With the completion of the double-blind, placebo-controlled treatment phase of the study, DBV remains on track to announce topline data from VITESSE in the fourth quarter of this year.

COSCIENS restructuring results in significantly lower cash outflow with operating expenses down 59% vs. Q3 2024.

ORLANDO -- Long-term results from trials of new drugs for hereditary angioedema (HAE) continue to support efficacy and safety ...

As Pfizer acquires MET-097 maker Metsera, phase 2 data show potential for greater tolerability and once-monthly dosing.

UBS Global Healthcare Conference 2025 November 10, 2025 3:30 PM ESTCompany ParticipantsDave Gancarz - Chief Business ...

Akebia Therapeutics shares retreated Monday after the company dropped plans for a Phase 3 clinical trial of its drug Vafseo for certain patients. Shares were trading at $1.66, down 19% and nearing the ...

Roche Holding (OTC: RHHBY) stock jumped 3.4% through 1:05 p.m. ET Monday after the pharmaceutical giant's Genentech subsidiary announced positive phase 3 clinical trial results for its fenebrutinib ...

From revolutionary CRISPR treatment to heavy drinking dangers, here's what you need to know about the latest health research.

Imneskibart will now enter late-stage trials after the drug offered durable tumour shrinkage in NSCLC, melanoma and other ...

Pioneering CRISPR trial shows single infusion permanently lowers bad cholesterol by 50% in patients who don't respond to medication.

One dose of an experimental drug cover offer lifetime treatment for people with high cholesterol, but its long-term safety is ...

Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with ...